Tirzepatide Dosage Guide: Escalation Schedule, Reconstitution & Unit Chart
Tirzepatide (GLP-2) 2.5–15 mg escalation as reported in published trials, reconstitution ratios, and mg-to-unit conversion tables.
By PX1 Research Team · August 4, 2026
Tirzepatide (GLP-2) escalation in the literature
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Published trial protocols are notable for how conservative the escalation is: a long initiation period followed by 2.5 mg steps at four-week intervals.
| Study phase | Reported weekly amount | Typical duration |
|---|---|---|
| Initiation | 2.5 mg | 4 weeks |
| Step 1 | 5 mg | 4 weeks |
| Step 2 | 7.5 mg | 4 weeks |
| Step 3 | 10 mg | 4 weeks |
| Step 4 | 12.5 mg | 4 weeks |
| Maximal | 15 mg | remainder |
Reported discontinuations in trials clustered in the first two steps and were predominantly gastrointestinal, which is why compressed escalation is not represented in the published data.
Reconstitution reference
A 30 mg vial with 3 mL bacteriostatic water gives 10 mg/mL:
| Target | Volume | Insulin units (U-100) |
|---|---|---|
| 2.5 mg | 0.25 mL | 25 |
| 5 mg | 0.50 mL | 50 |
| 7.5 mg | 0.75 mL | 75 |
| 10 mg | 1.00 mL | 100 |
Tirzepatide vs retatrutide in study data
Retatrutide adds glucagon-receptor agonism to the GIP/GLP-1 mechanism, and Phase 2 data reported larger weight-change effect sizes at the top arms — with a correspondingly higher adverse-event rate. Tirzepatide has the deeper published safety dataset. Full breakdown: Retatrutide vs Tirzepatide vs Semaglutide.
Product page: GLP-2 (Tirzepatide).
All figures below are reported from published laboratory literature and are provided for informational and laboratory-research context only. PX1 Research supplies compounds for laboratory and research use only — not for human or veterinary use.